Geert Jan Biessels
Professor of Neurology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Introduction: There is a need for measures of early stages of cerebral small vessel diseases (cSVDs). Recently, using 7T MRI, abnormalities of small vessel function were reported in patients with clinically manifest cSVD. The question is if such abnormalities are also present in early, covert stages of cSVD. We, therefore, studied the relation between cerebral small vessel function measures on 7T MRI and the burden of covert cSVD in the general aging population. Methods: Two hundred participants (mean age [years] ± SD: 71 ± 5, 43% women) without a history of stroke or dementia from the Rotterdam Study were included. Small vessel measures at 7T MRI, including perforating artery blood flow velocity and pulsatility and cerebrovascular reactivity (CVR) to carbon dioxide, were related to markers of cSVD burden at 1.5T MRI, including white matter hyperintensity (WMH) volume and microbleed, enlarged perivascular spaces, and lacune presence, using linear and logistic regression analyses. We also included cognitive performance as a clinical indicator of covert cSVD. Results: Across the population, neither perforating artery flow measures nor CVR were significantly associated with cSVD lesion burden or cognition, with small point estimates and no consistent direction of effects. Yet, within individuals, CVR was lower inside WMHs compared to normal-appearing white matter (CVR NAWM = 0.54 ± 0.48%; CVR WMH = 0.24 ± 0.94%; p = 0.006). Conclusion: Although these data confirm that vascular function is affected within WMH, we did not observe relations between small vessel function measures at 7T MRI and the burden of covert cSVD in this population-based sample. Apparently, these measures have limited sensitivity to early stages of cSVD.
Year:
2025
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 2050 1 . AD is highly heritable, with twin-based heritability estimates of 60-80% 2 . While 1,200 causal loci are predicted to exist for AD 3 , approximately 80 have been associated with AD in two recent studies 4,5 , suggesting that many loci remain to be discovered 6 . Here, we analyzed data from 183,620 AD cases and 2.6 million controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and identified microglia and, for the first time, several neuronal cell types enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a single-nucleotide polymorphism (SNP) heritability of 19%. Together, our findings offer insights into the genetic architecture and potential pathobiology of AD, as well as specific targets for future drug development research.
Year:
2025
Structured Abstract Background and Objectives Intracranial arteriosclerosis is a prevalent condition linked to serious health outcomes, such as stroke and dementia. It is hypothesized that intracranial arteriosclerosis compromises brain health by disrupting the functioning of adjacent vessels, including the middle cerebral artery (MCA) and the perforating small arteries downstream. Using 7T MRI, this study aims to assess the association between intracranial arteriosclerosis and cerebrovascular function in the MCA and in the downstream small perforating arteries. Methods This study is based on 195 participants (43.6% female, average age 70.8 years (± 4.52 years)) from the population-based Rotterdam Study who previously underwent a non-enhanced low-dose CT on which we measured intracranial carotid artery calcification (ICAC) and vertebral artery calcification (VAC) bilaterally as hallmark of intracranial arteriosclerosis. Participants underwent a 7T brain MRI to assess blood flow velocity and pulsatility in the MCA and small perforating arteries as well as whole-brain cerebrovascular reactivity (CVR). We assessed the relationship of left and right intracranial arteriosclerosis presence, burden, and subtypes with vessel function using linear regression and linear mixed models with a random intercept. Analyses were adjusted for age, sex and cardiovascular risk factors. Results The prevalence of ICAC was 77.4%. VAC prevalence was notably lower, at 10.3%. ICAC and VAC presence and burden were associated with higher pulsatility but not blood flow velocity in the MCA (e.g. β ICAC presence : 0.07 [95% Confidence interval: 0.02, 0.13]). There was no association with pulsatility or blood flow velocity in the small perforating arteries. Neither ICAC nor VAC were associated with CVR. Conclusions Intracranial arteriosclerosis influences pulsatility but not blood flow velocity in the MCA. This finding, combined with the absence of an effect between intracranial arteriosclerosis and cerebrovascular function further downstream, indicates that its impact is limited to cerebrovascular hemodynamics in adjacent vessels.
Year:
2025
Cerebrovascular disease is a major cause of cognitive decline and dementia. This is referred to as vascular cognitive impairment (VCI). Diagnosing VCI is important, among others to optimize treatment to prevent further vascular injury. This narrative review addresses challenges in current diagnostic approaches to VCI and potential future developments. First we summarize how diagnostic criteria for VCI evolved over time. We then highlight challenges in diagnosing VCI in clinical practice: assessment of severity of vascular brain injury on brain imaging is often imprecise and the relation between vascular lesion burden and cognitive functioning shows high intersubject variability. This can make it difficult to establish causality in individual patients. Moreover, because VCI is essentially an umbrella term, it lacks specificity on disease mechanisms, prognosis, and treatment. We see the need for a fundamentally different approach to diagnosing VCI, which should be more dimensional, including multimodal quantitative assessment of injury, with more accurate estimation of cognitive impact, and include biological definitions of disease that can support further development of targeted treatment. Recent developments in the field that can form the basis of such an approach are discussed.
Year:
2022
Collaborators (29)
Ruth Frikke-Schmidt
Professor, Chief Physician, MD PhD DMSc
-
Harro Seelaar
Neurologist
Erasmus MC
Paul O'Reilly
Associate Professor
Icahn School of Medicine at Mount Sinai
Meike W. Vernooij
Full professor
Erasmus University Medical Center
Clive Ballard
Pro-Vice Chancellor and Executive Dean
University of Exeter
Pieter Jelle Visser
Karolinska Institutet
Daniel Bos
Associate professor
Erasmus University Rotterdam
Jeroen Siero
Associate Professor
University Medical Center Groningen
Arvid Rongve
Professor
University of Bergen
Betty Tijms
Senior researcher
VU medisch centrum
Katja Scheffler
Associate Professor
Norwegian University of Science and Technology
Sara Hägg
Senior Researcher
Karolinska Institutet
Mohsen Ghanbari
Associate professor
Erasmus MC
Lasse Pihlstrøm
Professor
University of Oslo
Byron Creese
Senior Lecturer & Director of Research
Brunel University London
Chandra A Reynolds
Professor
University of Colorado Boulder
Jens Hjerling Leffler
Karolinska Institutet
Thomas Truelsen
University of Copenhagen
Christian Erikstrup
Chair Professor
Aarhus University
Wiesje van der Flier
Scientific director
VU medisch centrum
Alessandro Serretti
Docenti di ruolo di IIa fascia
Università degli Studi di Enna Kore
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
D.P. Wightman
University of Amsterdam
Julia Neitzel
-
Jaco J. M. Zwanenburg
Associate Professor of Quantitative Cerebrovascular MRI
Universitair Medisch Centrum Utrecht
Thomas Folkmann Hansen
Professor
Technical University of Denmark
Jian Zeng
The University of Queensland
Ole A. Andreassen
Oslo University Hospital
Frank J. Wolters
Associate professor
Erasmus University Rotterdam
Make your next move.
Prepare your application
Review drafts before you send them.